Identification of a new group of Chlamydia psittaci strains called TWAR

Cross immunity among strains of Chlamydia psittaci.

Chlamydia pneumoniae, strain TWAR.

A new third species of Chiamydia, called C pneumoniae, has been established for the TWAR organism. We first thought that the new organism belonged to the C psittaci species because it was clearly not a C trachomatis.2’8 Subsequent studies showed that the organism was unique from both currently recognized species.8”#{176}”7”9 Justification for establishing a new species rests primarily on studie...

A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Chlamydia pneumoniae strain TWAR, the new third species of Chlamydia, is a common cause of pneumonia and other acute respiratory tract infections. About 10% of hospitalized and outpatient pneumonia cases have been associated with TWAR infection. TWAR is among the four or five most commonly identified causes of all pneumonia. Most TWAR infections are mild or asymptomatic, but occasionally severe...

In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

The in vitro susceptibilities of two clinical isolates of Chlamydia pneumoniae from Brooklyn, N.Y., were determined for tetracycline, erythromycin, sulfamethoxazole, ciprofloxacin, and three new macrolides--azithromycin, clarithromycin, and roxithromycin. Clarithromycin was the most active drug tested, followed by the other macrolides, tetracycline, and ciprofloxacin.

A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis.

Chlamydia pneumoniae is a common cause of acute respiratory infections in humans. We evaluated mice as experimental animals for C. pneumoniae. Intranasal inoculation of Swiss Webster mice with C. pneumoniae induced a prolonged course of lung infection, as demonstrated by reisolation of organisms from lungs (at 42 days) and persistence of lung pathology (> 60 days). The lung pathology was charac...